Brooks Laboratories

Brooks Laboratories Enterprise Value

The Enterprise Value (EV) of Brooks Laboratories (BROOKS.NS) as of Nov 17, 2026 is 1.69 B INR. In the previous year, Enterprise Value (EV) was 1.74 B INR — a change of -3.08% (lower).

Enterprise Value

1.69 BINR

YoY

-3.08%

Last updated:

Enterprise Value (EV) of Brooks Laboratories is 2026 1.69 B INR. Enterprise Value (EV) of Brooks Laboratories was 2025 1.74 B INR. It decreases by -3.08% lower compared to the previous year.

The Brooks Laboratories Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
1.97 B INR
Jan 1, 2020
1.95 B INR
Jan 1, 2021
1.99 B INR
Jan 1, 2022
1.91 B INR
Jan 1, 2023
1.75 B INR
Jan 1, 2024
1.74 B INR
Jan 1, 2025
1.74 B INR
Jan 1, 2026
1.69 B INR
The Brooks Laboratories Enterprise Value history
YEAREnterprise ValueYoY
1.69 BINR-3.08%
1.74 BINR+0.47%
1.74 BINR-0.56%
1.75 BINR-8.47%
1.91 BINR-3.95%
1.99 BINR+1.67%
1.95 BINR-0.73%
1.97 BINR+0.85%
1.95 BINR+8.86%
1.79 BINR+4.47%
1.72 BINR+17.77%
1.46 BINR+5.38%
1.38 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Brooks Laboratories Stock analysis

What does Brooks Laboratories do? Brooks Laboratories Ltd. manufactures pharmaceutical products including Carbapenem category drugs such as Imipenem 250mg + Cilastatin 250mg, Meropenem 125mg, and Doripenem 500mg. The company produces Penicillins in injections, tablets, and dry syrup forms, along with General category products like liquid injections, dry powder injections, and eye/ear drops. Brooks Laboratories markets its pharmaceuticals nationally and internationally to regulated markets through its manufacturing plants in Baddi, Himachal Pradesh. The firm generates revenue by selling these dosage forms to healthcare providers and distributors in regulated pharmaceutical markets. The company's product portfolio includes specific formulations like Iron sucrose 100mg/5ml liquid injections under the General category. Brooks Laboratories targets regulated markets globally for its Carbapenem, Penicillin, and General category products. Its manufacturing operations at Baddi enable nationwide and international distribution of pharmaceuticals. Revenue is derived from the sale of these branded and generic pharmaceutical products to hospitals, pharmacies, and international buyers in compliant markets. Brooks Laboratories focuses on producing injectable and oral dosage forms including tablets, dry syrup, and eye/ear drops. The company's Carbapenem category features Meropenem 1000mg+Tazobactam 500mg and Doripenem 1000mg. Penicillins are available as injections, tablets, and dry syrup. The firm's revenue model relies on direct sales of these pharmaceutical products to healthcare institutions and distributors in regulated markets, ensuring compliance with international pharmaceutical standards. Brooks Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Brooks Laboratories stock

Enterprise Value (EV) of Brooks Laboratories is 1.69 B INR in 2026.

Enterprise Value (EV) of Brooks Laboratories changed from 1.74 B INR to 1.69 B INR, representing a -3.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Brooks Laboratories since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s INR, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' INR varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Brooks Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Brooks Laboratories

All Key Metrics — Brooks Laboratories